Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Aug 7, 2020 8:35 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

August 7, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz , president and chief executive officer

Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

August 6, 2020

Rolling NDA submission for maralixibat in Alagille syndrome (ALGS) to be initiated in third quarter 2020; planning for potential launch in second half of 2021. Submission of European marketing authorization application for maralixibat in PFIC2 planned for fourth quarter of 2020.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jul. 10, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 11, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation

Events

Canaccord Genuity 40th Annual Growth Conference

Aug 13, 2020 at 3:00 PM EDT

Add to Outlook

Add to Google Calendar

Jefferies 2020 Healthcare Conference

Jun 2, 2020 at 1:00 PM EDT

Listen to webcast

Raymond James 41st Annual Institutional Investors Conference

Mar 4, 2020 at 9:15 AM EST

Listen to webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu